Have a personal or library account? Click to login
Telomere length and TERT polymorphisms as biomarkers in asbestos-related diseases Cover

Telomere length and TERT polymorphisms as biomarkers in asbestos-related diseases

Open Access
|Feb 2024

References

  1. Toyokuni S. Commentary on “mechanisms of asbestos-induced carcinogenesis” published in 2009. Nagoya J Med Sci 2023; 85: 13–5. doi: <a href="https://doi.org/10.18999/nagjms.85.1.13" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.18999/nagjms.85.1.13</a>
  2. Hajj GNM, Cavarson CH, Pinto CAL, Venturi G, Navarro JR, de Lima VCC.. Malignant pleural mesothelioma: an update. J Bras Pneumol 2021; 47: e20210129. doi: <a href="https://doi.org/10.36416/1806-3756/e20210129" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.36416/1806-3756/e20210129</a>
  3. Brims F. Epidemiology and clinical aspects of malignant pleural mesothelioma. Cancers 2021; 13: 4194. doi: <a href="https://doi.org/10.3390/cancers13164194." target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.3390/cancers13164194.</a>
  4. Gaudino G, Xue J, Yang H. How asbestos and other fibers cause mesothelioma. Transl Lung Cancer Res 2020; 9(Suppl 1): S39–46. doi: <a href="https://doi.org/10.21037/tlcr.2020.02.01" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.21037/tlcr.2020.02.01</a>
  5. Tallet A, Nault JC, Renier A Hysi I, Galateau-Sallé F, A Cazes A, et al. Overexpression and promoter mutation of the TERT gene in malignant pleural mesothelioma. Oncogene 2014; 33: 3748–52. doi: <a href="https://doi.org/10.1038/onc.2013.351" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1038/onc.2013.351</a>
  6. Rossiello F, Jurk D, Passos JF, di Fagagna FA. Telomere dysfunction in ageing and age-related diseases. Nat Cell Biol 2022; 24: 135–47. doi: <a href="https://doi.org/10.1038/s41556-022-00842-x" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1038/s41556-022-00842-x</a>
  7. Lin J, Epel E. Stress and telomere shortening: insights from cellular mechanisms. Ageing Res Rev 2022; 73: 101507. doi: <a href="https://doi.org/10.1016/j.arr.2021.101507" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1016/j.arr.2021.101507</a>
  8. Wadowski B, De Rienzo A, Bueno R. The molecular basis of malignant pleural mesothelioma. Thorac Surg Clin 2020; 30: 383–93. doi: <a href="https://doi.org/10.1016/j.thorsurg.2020.08.005" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1016/j.thorsurg.2020.08.005</a>
  9. Berry TA, Belluso E, Vigliaturo R, Gieré R, Emmett EA, Testa JR, et al. Asbestos and other hazardous fibrous minerals: potential exposure pathways and associated health risks. Int J Environ Res Public Health 2022; 19: 4031. doi: <a href="https://doi.org/10.3390/ijerph19074031" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.3390/ijerph19074031</a>
  10. Pouliquen DL, Kopecka J. Malignant mesothelioma. Cancers 2021; 13: 3447. doi: <a href="https://doi.org/10.3390/cancers13143447" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.3390/cancers13143447</a>
  11. Zhu W, Liu J, Li Y, Shi Z, Wei S. Global, regional, and national trends in mesothelioma burden from 1990 to 2019 and the predictions for the next two decades. SSM Popul Health 2023; 23: 101441. doi: <a href="https://doi.org/10.1016/j.ssmph.2023.101441" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1016/j.ssmph.2023.101441</a>
  12. Cancer in Slovenia 2018. Annual report. Zadnik V, Gašljević G, Hočevar M, Jarm K, Pompe-Kirn V, Strojan P, et al, editors. Ljubljana: Institute of Oncology Ljubljana, Epidemiology and Cancer Registry, Slovenian Cancer Registry; 2020.
  13. Štrbac, D, Dolžan V. Novel and future treatment options in mesothelioma: a systematic review. Int J Mo Sci 2022; 23: 1975. doi: <a href="https://doi.org/10.3390/ijms23041975" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.3390/ijms23041975</a>
  14. Guo X, Lin L, Zhu J. Immunotherapy vs. chemotherapy in subsequent treatment of malignant pleural mesothelioma: which is better? J Clin Med 2023; 12: 2531. doi:<a href="https://doi.org/10.3390/jcm12072531" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.3390/jcm12072531</a>
  15. Okamoto K, Seimiya H. Revisiting telomere shortening in cancer. Cells 2019; 8: 107. doi: <a href="https://doi.org/10.3390/cells8020107" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.3390/cells8020107</a>
  16. Razgonova MP, Zakharenko AM, Golokhvast KS, Thanasoula M, Sarandi E, Nikolouzakis K, et al. Telomerase and telomeres in aging theory and chronographic aging theory (review). Mol Med Rep 2020; 22: 1679–94. doi: <a href="https://doi.org/10.3892/mmr.2020.11274" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.3892/mmr.2020.11274</a>
  17. Rampazzo E, Cecchin E, Del Bianco P, Menin C, Spolverato G, Giunco S, et al. Genetic variants of the TERT gene. telomere length, and circulating TERT as prognostic markers in rectal cancer patients. Cancers 2020; 12: 3115. doi: <a href="https://doi.org/10.3390/cancers12113115" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.3390/cancers12113115</a>
  18. Yuan X, Dai M, Xu D. Telomere-related markers for cancer. Curr Top Med Chem 2020; 20: 410–32. doi: <a href="https://doi.org/10.2174/1568026620666200106145340" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.2174/1568026620666200106145340</a>
  19. Levstek T, Redenšek S, Trošt M, Dolžan V, Trebušak Podkrajšek K. Assessment of the telomere length and its effect on the symptomatology of parkinson’s disease. Antioxidants 2021; 10: 137. doi: <a href="https://doi.org/10.3390/antiox10010137" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.3390/antiox10010137</a>
  20. Borges G, Criqui M, Harrington L. Tieing together loose ends: telomere instability in cancer and aging. Mol Oncol 2022; 16: 3380–96. doi: <a href="https://doi.org/10.3390/antiox10010137" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.3390/antiox10010137</a>
  21. Cigan SS, Meredith JJ, Kelley AC, Yang T, Langer EK, Hooten AJ, et al. Predicted leukocyte telomere length and risk of germ cell tumours. Br J Cancer 2022; 127: 301–12. doi: <a href="https://doi.org/10.1038/s41416-022-01798-3" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1038/s41416-022-01798-3</a>
  22. Au AY, Hackl T, Yeager TR, Cohen SB, Pass HI, Harris CC, et al. Telomerase activity in pleural malignant mesotheliomas. Lung Cancer 2011; 73: 283–8. doi: <a href="https://doi.org/10.1016/j.lungcan.2010.12.023" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1016/j.lungcan.2010.12.023</a>
  23. Aida S, Aida J, Naoi M, Kato M, Tsuura Y, Natsume I, et al. Measurement of telomere length in cells from pleural effusion: asbestos exposure causes telomere shortening in pleural mesothelial cells. Pathol Int 2018; 68: 503–8. doi: <a href="https://doi.org/10.1111/pin.12710" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1111/pin.12710</a>
  24. Alfudhili KM, Lynch DA, Laurent F, Ferretti GR, Dunet V, Beigelman-Aubry C. et al. Focal pleural thickening mimicking pleural plaques on chest computed tomography: tips and tricks. Br J Radiol 2016; 89: 20150792. doi: <a href="https://doi.org/10.1259/bjr.20150792" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1259/bjr.20150792</a>
  25. Kim Y, Myong JP, Lee JK, Kim JS, Kim YK, Jung SH, et al. CT characteristics of pleural plaques related to occupational or environmental asbestos exposure from South Korean asbestos mines. Korean J Radiol 2015; 16: 1142–52. doi: <a href="https://doi.org/10.3348/kjr.2015.16.5.1142" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.3348/kjr.2015.16.5.1142</a>
  26. Wolff H, Vehmas T, Oksa P, Rantanen J, Vainio H. Asbestos, asbestosis, and cancer, the Helsinki criteria for diagnosis and attribution 2014: recommendations. Scand J Work Environ Health 2015; 41: 5–15. doi: <a href="https://doi.org/10.5271/sjweh.3462" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.5271/sjweh.3462</a>
  27. Chapel DB, Schulte JJ, Husain AN, Krausz T. Application of immunohistochemistry in diagnosis and management of malignant mesothelioma. Transl Lung Cancer Res 2020; 9(Suppl 1): S3–27. doi: <a href="https://doi.org/10.21037/tlcr.2019.11.29" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.21037/tlcr.2019.11.29</a>
  28. Munkholm-Larsen S, Cao CQ, Yan TD. Malignant peritoneal mesothelioma. World J Gastrointest Surg 2009; 1: 38–48. doi: <a href="https://doi.org/10.4240/wjgs.v1.i1.38" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.4240/wjgs.v1.i1.38</a>
  29. Berzenji L, Van Schil PE, Carp L. The eighth TNM classification for malignant pleural mesothelioma. Transl Lung Cancer Res 2018; 7: 543–9. doi: <a href="https://doi.org/10.21037/tlcr.2018.07.05" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.21037/tlcr.2018.07.05</a>
  30. Franko A, Goricar K, Kovac V, Dodic-Fikfak M, Dolzan V. NLRP3 and CARD8 polymorphisms influence risk for asbestos-related diseases. J Med Biochem 2020; 39: 91–9. doi: <a href="https://doi.org/10.2478/jomb-2019-0025" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.2478/jomb-2019-0025</a>
  31. Klebe S, Leigh J, Henderson DW, Nurminen M. Asbestos. smoking and lung cancer: an update. Int J Environ Res Public Health 2019; 17: 258. doi: <a href="https://doi.org/10.3390/ijerph17010258" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.3390/ijerph17010258</a>
  32. Levstek T, Redenšek S, Trošt M, Dolžan V, Trebušak Podkrajšek K. Assessment of the telomere length and its effect on the symptomatology of Parkinson’s disease. Antioxidants 2021; 10: 137. doi: <a href="https://doi.org/10.3390/antiox10010137." target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.3390/antiox10010137.</a>
  33. Lulkiewicz M, Bajsert J, Kopczynski P, Barczak W, Rubis B. Telomere length: how the length makes a difference. Mol Biol Rep 2020; 47: 7181–8. doi: <a href="https://doi.org/10.1007/s11033-020-05551-y" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1007/s11033-020-05551-y</a>
  34. Havas A, Yin S, Adams PD. The role of aging in cancer. Mol Oncol 2022; 16: 3213–9. doi: <a href="https://doi.org/10.1002/1878-0261.13302" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1002/1878-0261.13302</a>
  35. Kusamura S, Baratti D, De Simone M, Pasqual EM, Ansaloni L, Marrelli D, et al. Diagnostic and therapeutic pathway in diffuse malignant peritoneal mesothelioma. Cancers 2023; 15: 662. doi: <a href="https://doi.org/10.3390/cancers15030662" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.3390/cancers15030662</a>
  36. Zhou M, Jiang B, Xiong M, Zhu X. Association between TERT rs2736098 polymorphisms and cancer risk-a meta-analysis. Front Physiol 2018; 9: 377. doi: <a href="https://doi.org/10.3389/fphys.2018.00377" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.3389/fphys.2018.00377</a>
  37. Wang M, Sun Y. Telomerase reverse transcriptase rs2736098 polymorphism is associated with lung cancer: a meta-analysis. J Int Med Res 2020; 48: 300060520936173. doi: <a href="https://doi.org/10.1177/0300060520936173" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1177/0300060520936173</a>
  38. Holesova Z, Krasnicanova L, Saade R, Pös O, Budis J, Gazdarica J, et al. Telomere length changes in cancer: insights on carcinogenesis and potential for non-invasive diagnostic strategies. Genes 2023; 14: 715. doi: <a href="https://doi.org/10.3390/genes14030715" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.3390/genes14030715</a>
  39. Arimura-Omori M, Kiyohara C, Yanagihara T, Yamamoto Y, Ogata-Suetsugu S, Harada E, et al. Association between telomere-related polymorphisms and the risk of IPF and COPD as a precursor lesion of lung cancer: findings from the Fukuoka tobacco-related lung disease (FOLD) registry. Asian Pac J Cancer Prev 2020; 21: 667–73. doi: <a href="https://doi.org/10.31557/APJCP.2020.21.3.667" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.31557/APJCP.2020.21.3.667</a>
  40. Cornean CI, Catana A, Maniu AA, Do polymorphisms of the TERT, GSTM1, and GSTT1 genes increase laryngeal cancer susceptibility in smokers of Romanian descent? Medicina (Kaunas) 2022; 58: 1106. doi: <a href="https://doi.org/10.3390/medicina5808110" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.3390/medicina5808110</a>
  41. He G, Song T, Zhang Y, Chen X, W, Chen H, et al. TERT rs10069690 polymorphism and cancers risk: a meta-analysis. Mol Genet Genomic Med 2019; 7: e00903. doi: <a href="https://doi.org/10.1002/mgg3.903" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1002/mgg3.903</a>
  42. Benitez-Buelga C, Sanchez-Barroso L, Gallardo M, Apellániz-Ruiz M, Inglada-Pérez L, Yanowski K, et al. Impact of chemotherapy on telomere length in sporadic and familial breast cancer patients. Breast Cancer Res Treat 2015; 149: 385–94. doi: <a href="https://doi.org/10.1007/s10549-014-3246-6" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1007/s10549-014-3246-6</a>
  43. Zins K, Peka E, Miedl H, Ecker S, Abraham D, Schreiber M. Association of the telomerase reverse transcriptase rs10069690 polymorphism with the risk, age at onset and prognosis of triple negative breast cancer. Int J Mol Sci 2023; 24: 1825. doi: <a href="https://doi.org/10.3390/ijms24031825" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.3390/ijms24031825</a>
  44. Schneider CV, Schneider KM, Teumer A, Rudolph KL, Hartmann D, Rader DJ, et al. Association of telomere length with risk of disease and mortality. JAMA Intern Med 2022; 182: 291–300. doi: <a href="https://doi.org/10.1001/jamainternmed.2021.7804" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1001/jamainternmed.2021.7804</a>
  45. Hamada T, Yuan C, Bao Y, Mingfeng Zhang, Natalia Khalaf, Ana Babic, et al. Prediagnostic leukocyte telomere length and pancreatic cancer survival. Cancer Epidemiol Biomarkers Prev 2019; 28: 1868–75. doi: <a href="https://doi.org/10.1158/1055-9965.EPI-19-0577" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1158/1055-9965.EPI-19-0577</a>
  46. Ma R, Liu C, Lu M, Yuan X, Cheng G, Kong F, et al. The TERT locus genotypes of rs2736100-CC/CA and rs2736098-AA predict shorter survival in renal cell carcinoma. Urol Oncol 2019; 37: 301.e1–10. doi: <a href="https://doi.org/10.1016/j.urolonc.2019.01.014" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1016/j.urolonc.2019.01.014</a>
  47. Pandith AA, Wani ZA, Qasim I, Afroze D, Manzoor U, Amin I, et al. Association of strong risk of hTERT gene polymorphic variants to malignant glioma and its prognostic implications with respect to different histological types and survival of glioma cases. J Gene Med 2020; 22: e3260. doi: <a href="https://doi.org/10.1002/jgm.3260" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1002/jgm.3260</a>
  48. Nie X, Shang J, Wang W. TERT genetic polymorphism rs2736100 is associated with an aggressive manifestation of papillary thyroid carcinoma. Front Surg 2022; 9: 1019180. doi: <a href="https://doi.org/10.3389/fsurg.2022.1019180" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.3389/fsurg.2022.1019180</a>
DOI: https://doi.org/10.2478/raon-2024-0009 | Journal eISSN: 1581-3207 | Journal ISSN: 1318-2099
Language: English
Page range: 87 - 98
Submitted on: Aug 25, 2023
Accepted on: Sep 13, 2023
Published on: Feb 21, 2024
Published by: Association of Radiology and Oncology
In partnership with: Paradigm Publishing Services
Publication frequency: 4 times per year

© 2024 Ana Mervic, Katja Goricar, Tanja Blagus, Alenka Franko, Katarina Trebusak-Podkrajsek, Metoda Dodic Fikfak, Vita Dolzan, Viljem Kovac, published by Association of Radiology and Oncology
This work is licensed under the Creative Commons Attribution 4.0 License.